OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BIBB.TE55

BibbInstruments AB

Advanced Medical Equipment & TechnologyVerified

BibbInstruments AB has a current liquidity position characterized by a current ratio of 2.03, indicating that the company holds twice as many current assets as current liabilities. However, the company reported negative operating cash flow of -1.572 million SEK and free cash flow of -4.404 million SEK, suggesting ongoing cash burn and limited ability to fund operations without external financing. The absence of long-term debt and a debt-to-equity ratio of 0.0 implies that the company is not leveraging debt to finance its operations, which may limit its growth potential. Profitability metrics for BibbInstruments AB are negative, with a return on equity of -10.52% and a return on assets of -9.41%, both significantly below the industry median for Advanced Medical Equipment & Technology firms. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to produce profit. The company's revenue is reported as 0.0 SEK, which suggests either a reporting anomaly or a very early-stage business with no revenue generation yet. There is no disclosed segment or geographic breakdown of revenue, making it difficult to assess the company's exposure to different markets or product lines. Looking ahead, the company is expected to continue experiencing negative cash flows, with no clear indication of a turnaround in the near term. The absence of revenue and the ongoing cash burn raise concerns about the company's ability to scale or achieve profitability in the next fiscal year. Risk factors for BibbInstruments AB include the high burn rate and lack of revenue, which could lead to liquidity constraints if external financing is not secured. The company has no immediate filing-based liquidity or dilution flags, and the dilution risk is currently assessed as low. However, the absence of long-term debt and the current equity base of 28.247 million SEK may not be sufficient to sustain operations without additional capital. Recent filings and transcripts do not provide any new insights into the company's operations or strategic direction. The company appears to be in a pre-revenue phase, with no disclosed major product launches or customer contracts that could signal a path to profitability.

30-day price · BIBB.TE+0.09 (+23.2%)
Low$0.35High$0.60Close$0.50As of17 May, 00:00 UTC
Profile
CompanyBibbInstruments AB
TickerBIBB.TE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. BibbInstruments AB develops and sells advanced medical equipment and technology, primarily focused on healthcare diagnostics and monitoring solutions.

Classification. BibbInstruments AB is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a high confidence level of 0.92.

BibbInstruments AB has a current liquidity position characterized by a current ratio of 2.03, indicating that the company holds twice as many current assets as current liabilities. However, the company reported negative operating cash flow of -1.572 million SEK and free cash flow of -4.404 million SEK, suggesting ongoing cash burn and limited ability to fund operations without external financing. The absence of long-term debt and a debt-to-equity ratio of 0.0 implies that the company is not leveraging debt to finance its operations, which may limit its growth potential. Profitability metrics for BibbInstruments AB are negative, with a return on equity of -10.52% and a return on assets of -9.41%, both significantly below the industry median for Advanced Medical Equipment & Technology firms. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to produce profit. The company's revenue is reported as 0.0 SEK, which suggests either a reporting anomaly or a very early-stage business with no revenue generation yet. There is no disclosed segment or geographic breakdown of revenue, making it difficult to assess the company's exposure to different markets or product lines. Looking ahead, the company is expected to continue experiencing negative cash flows, with no clear indication of a turnaround in the near term. The absence of revenue and the ongoing cash burn raise concerns about the company's ability to scale or achieve profitability in the next fiscal year. Risk factors for BibbInstruments AB include the high burn rate and lack of revenue, which could lead to liquidity constraints if external financing is not secured. The company has no immediate filing-based liquidity or dilution flags, and the dilution risk is currently assessed as low. However, the absence of long-term debt and the current equity base of 28.247 million SEK may not be sufficient to sustain operations without additional capital. Recent filings and transcripts do not provide any new insights into the company's operations or strategic direction. The company appears to be in a pre-revenue phase, with no disclosed major product launches or customer contracts that could signal a path to profitability.
Key takeaways
  • BibbInstruments AB is in a pre-revenue phase with negative cash flows and no disclosed revenue.
  • The company has a strong liquidity position in terms of the current ratio but is burning cash at a high rate.
  • Return on equity and return on assets are significantly negative, indicating poor profitability.
  • The company is not leveraging debt, which may limit its growth potential.
  • No immediate liquidity or dilution risks are flagged, but the lack of revenue and ongoing losses raise concerns about long-term viability.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$0.00
Gross profit$0.00
Operating income-$3.0M
Net income-$3.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.6M
CapEx-$1.5M
Free cash flow-$4.4M
Total assets$31.6M
Total liabilities$3.3M
Total equity$28.2M
Cash & equivalents
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$16.0k-$10.3M-$10.3M-$14.9M
FY-3$0.00-$11.3M-$11.3M-$16.7M
FY-2$0.00-$11.2M-$11.0M-$14.0M
FY-1$0.00-$12.8M-$12.7M-$17.5M
FY0$401.0k-$14.7M-$14.6M-$17.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$23.5M$21.5M
FY-3$34.8M$31.8M
FY-2$33.4M$31.2M
FY-1$33.7M$28.4M
FY0$40.2M$37.6M
PeriodOCFCapExFCFSBC
FY-4-$10.1M-$4.8M-$14.9M
FY-3-$9.3M-$5.7M-$16.7M
FY-2-$11.7M-$3.4M-$14.0M
FY-1-$13.0M-$5.3M-$17.5M
FY0-$13.6M-$4.5M-$17.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$0.00-$3.0M-$3.0M-$4.4M
FQ-6$0.00-$3.6M-$3.6M-$4.4M
FQ-5$0.00-$2.5M-$2.4M-$3.4M
FQ-4$0.00-$3.8M-$3.8M-$5.3M
FQ-3$39.0k-$2.9M-$2.9M-$4.2M
FQ-2$0.00-$3.9M-$3.8M-$5.3M
FQ-1$110.0k-$2.8M-$2.8M-$4.3M
FQ0$253.0k-$5.1M-$5.1M-$3.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$31.6M$28.2M
FQ-6$37.2M$34.5M
FQ-5$33.8M$32.1M
FQ-4$33.7M$28.4M
FQ-3$50.0M$47.8M
FQ-2$48.0M$45.5M
FQ-1$44.5M$42.7M
FQ0$40.2M$37.6M
PeriodOCFCapExFCFSBC
FQ-7-$1.6M-$1.5M-$4.4M
FQ-6-$5.7M-$2.5M-$4.4M
FQ-5-$9.3M-$3.6M-$3.4M
FQ-4-$13.0M-$5.3M-$5.3M
FQ-3-$1.8M-$1.4M-$4.2M
FQ-2-$5.5M-$3.0M-$5.3M
FQ-1-$8.9M-$4.6M-$4.3M
FQ0-$13.6M-$4.5M-$3.8M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$28.2M
Net cash
Current ratio2.0
Debt/Equity0.0
ROA-9.4%
ROE-10.5%
Cash conversion53.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricBIBB.TEActivity
Op margin-16.5% medp25 -174.5% · p75 8.8%
Net margin-16.5% medp25 -172.4% · p75 8.4%
Gross margin47.4% medp25 34.2% · p75 65.3%
CapEx / revenue-5.4% medp25 -12.5% · p75 -2.2%
Debt / equity0.0%4.3% medp25 0.0% · p75 28.0%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 02:14 UTC#f2be5de5
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 12:11 UTCJob: 22a755a6